PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study

doi:10.21037/tcr-20-1333

HFCAS OpenIR

	PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study
	Wei, Qing 1,2; Yuan, Xing 1,2; Li, Jingjing 1,2; Xu, Qi 1,2; Ying, Jieer 1,2
	2020-09-01
发表期刊	TRANSLATIONAL CANCER RESEARCH
ISSN	2218-676X
通讯作者	Xu, Qi(hzxuqi@sina.cn) ; Ying, Jieer(jieerying@aliyun.com)
摘要	Background: Nivolumab and pembrolizumab were approved as immune checkpoint inhibitors for third-line treatment of advanced gastric or esophagogastric junction cancer (GC/EGJC) in 2017. However, immunotherapy monotherapy has low efficacy. Apatinib has been proven effective in advanced GC/EGJC. Numerous studies have shown that immunotherapy has a synergistic effect when combined with targeted drug therapy. Based on these facts and to assess the efficacy and safety of programmed death 1 (PD-1) inhibitor and apatinib as combination therapy in patients (pts) with unresectable locally advanced or metastatic GC/EGJC, a retrospective clinical research study was carried out. Methods: Pts (n=24) received PD-1 inhibitor and apatinib (250 mg once daily) as second- or third-line therapy in this observational, retrospective study. The primary objectives were efficacy and safety. Results: At data cut-off (December 31, 2019), 24 pts were enrolled. Of the 19 pts who were evaluable, the objective response rate (ORR) was 26.3% (5/19), the median progression-free survival (PFS) was 3.0 (95% CI: 1.3 to 4.7) months, and the median overall survival (OS) was not reached. Grade 3 or 4 treatment-related adverse events (TRAEs) occurred in 3 (15.8%) of the 19 pts. These adverse events (AEs) included pruritus, rash, hand-foot syndrome, and increased aspartate aminotransferase (AST) or alanine aminotransferase (ALT). No treatment-related deaths occurred. Conclusions: Combination therapy of PD-1 inhibitor and apatinib showed encouraging clinical activity and demonstrated tolerable toxicity in pts with advanced GC/EGJC. Hence, our work provide rationale for the combination of PD-1 inhibitor and apatinib in advanced GC/EGJC.
关键词	Programmed death 1 (PD-1) gastric cancer (GC) immune checkpoint inhibitors immunotherapy apatinib
DOI	10.21037/tcr-20-1333
关键词[WOS]	TUMOR MICROENVIRONMENT ; DOUBLE-BLIND ; IMMUNOTHERAPY ; CHEMOTHERAPY ; VASCULATURE ; THERAPIES ; BLOCKADE
收录类别	SCI
语种	英语
资助项目	Zhejiang Chinese Medicine Science and Technology Program[2018ZB022]
项目资助者	Zhejiang Chinese Medicine Science and Technology Program
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000575123400020
出版者	AME PUBL CO
引用统计	被引频次：6[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/104300
专题	中国科学院合肥物质科学研究院
通讯作者	Xu, Qi; Ying, Jieer
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Abdominal Med Oncol, Hangzhou, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Wei, Qing,Yuan, Xing,Li, Jingjing,et al. PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study[J]. TRANSLATIONAL CANCER RESEARCH,2020,9.
APA	Wei, Qing,Yuan, Xing,Li, Jingjing,Xu, Qi,&Ying, Jieer.(2020).PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study.TRANSLATIONAL CANCER RESEARCH,9.
MLA	Wei, Qing,et al."PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study".TRANSLATIONAL CANCER RESEARCH 9(2020).